AN OPEN-LABEL, PARALLEL-GROUP, PHARMACOKINETIC STUDY OF MULTIPLE INTRAVENOUS DOSES OF AZTREONAM AND AVIBACTAM IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT AND NORMAL RENAL FUNCTION
Latest Information Update: 02 Aug 2023
Price :
$35 *
At a glance
- Drugs Avibactam/aztreonam (Primary)
- Indications Gram-negative infections; Intra-abdominal infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 02 Nov 2021 Status changed from recruiting to completed.
- 15 Sep 2021 Planned End Date changed from 14 Oct 2021 to 25 Oct 2021.
- 15 Sep 2021 Planned primary completion date changed from 14 Oct 2021 to 22 Sep 2021.